Zenocutuzumab Shows Efficacy in Patients with Advanced NRG1 Fusion-positive Cancers By Ogkologos - February 19, 2025 173 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the eNRGy study Source RELATED ARTICLESMORE FROM AUTHOR Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Cabozantinib and Nivolumab March 4, 2021 The Investigational PD1 Antibody, Tislelizumab, Shows Promise in Patients With Unresectable... July 1, 2021 Can Getting a “Base Tan” Protect You From Sunburn and Skin... March 30, 2023 Long-Term Clinical Benefit with Nivolumab Plus Ipilimumab Extends Beyond Treatment Discontinuation... October 18, 2022 Load more HOT NEWS Precision drug slows progression of advanced breast cancer News digest – ovarian cancer blood test, statins, spending review and... Researchers Believe Antibodies from Alpacas Could Be Key to Curing Cancer,... A Large Case-Control Study of Hodgkin Lymphoma Survivors Suggests a Dose-Response...
